Drug Insights

Expert Tips for Searching Doxepin on Synapse

15 March 2024
2 min read

Doxepin, the small molecule drug, serves as a cogent therapeutic agent, targeting both the norepinephrine transporter (NET) and serotonin transporter subtype 5 (SERT-5). Through the dual action of inhibiting the reuptake of both norepinephrine and serotonin in the brain, doxepin functions as a resplendent antidepressant, leading to an escalation in the levels of these neurotransmitters within the synaptic cleft. This neurochemical alteration helps to stabilize mood, mitigate anxiety, and augment sleep quality, thereby yielding numerous benefits. From its inception, in September 1969, doxepin has been the beacon of hope for those struggling with depression, anxiety disorders, and insomnia. Nonetheless, it is imperative to be cognizant of the fact that doxepin can induce some untoward effects, including, but not limited to, drowsiness, dry mouth, constipation, and weight gain, and may even interact with other medications. Therefore, it is judicious to utilize doxepin with due caution under the discerning guidance of a healthcare professional. Click on the image below to begin the exploration journey of Doxepin through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Pfizer Announces Positive Phase III Results for ADCETRIS® in Treating Resistant Large B-cell Lymphoma
Latest Hotspot
3 min read
Pfizer Announces Positive Phase III Results for ADCETRIS® in Treating Resistant Large B-cell Lymphoma
15 March 2024
Pfizer Reveals Favorable Survival Data from Stage III Study of ADCETRIS® for Recurrent/Resistant Large B-cell Lymphoma Treatment.
Read →
Atai Strategic Investment in Beckley Psytech to Jointly Develop Rapid-Acting Psychedelic Medications for the Treatment of Depression
DrugDeal Decode
5 min read
Atai Strategic Investment in Beckley Psytech to Jointly Develop Rapid-Acting Psychedelic Medications for the Treatment of Depression
15 March 2024
clinical-stage biopharma atai Life Sciences (NASDAQ: ATAI), focused on transforming mental health treatment, announced a strategic investment in Beckley Psytech, cementing its position as the bio-pharma leader with the broadest portfolio of clinical-stage psychedelic drug candidates.
Read →
Longbio Pharma Presents Promising LP-003 Drug Data at AAD 2024
Latest Hotspot
3 min read
Longbio Pharma Presents Promising LP-003 Drug Data at AAD 2024
15 March 2024
At the 2024 AAD conference, Longbio Pharma showcased encouraging early-stage findings for their drug LP-003.
Read →
Navigating Health Information: How to Use Synapse to Search for Fenofibrate
Drug Insights
2 min read
Navigating Health Information: How to Use Synapse to Search for Fenofibrate
15 March 2024
Fenofibrate, the small molecule drug, possesses a unique ability to target the peroxisome proliferator-activated receptor alpha (PPARα) as an agonist.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.